Skip to main content

Table 2 Number of participants in each AZD0530 treatment group experiencing an adverse event

From: A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

  Treatment group (AZD0539 dose; n = 6 per group)  
Adverse event Placebo 50 mg 100 mg 125 mg Total
Any adverse event* 3 4 5 4 16
Diarrhea 2 0 1 2 5
Headache 2 1 1 1 5
Fatigue 1 0 0 2 3
Nausea 2 0 0 1 3
Pneumonia, atypical/bronchitis 0 0 0 1 1
Congestive heart failure 0 0 0 1 1
Renal insufficiency, worsened 0 0 0 1 1
Elevated serum creatinine 0 0 0 1 1
Cough, worsened 0 0 0 1 1
Postnasal drip 0 0 0 1 1
Pulmonary hypertension 0 0 0 1 1
Anorexia 0 0 0 1 1
Tinnitus 0 0 0 1 1
Myalgias 0 0 0 1 1
Squamous cell carcinoma 0 0 1 0 1
Basal cell carcinoma 0 0 1 0 1
Wrist pain 0 0 1 0 1
Noncardiac chest pain 0 0 1 0 1
Upper respiratory infection 0 1 0 0 1
Flu-like symptoms 0 1 0 0 1
Lightheadedness 0 1 0 0 1
Vomiting 1 0 0 0 1
  1. *Includes participants who reported at least one adverse event. The effect of treatment group is not significant for any adverse event or individual adverse events (Fisher’s exact test, P > 0.05).